Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Clin Nutr ; 101(3): 487-95, 2015 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25733633

RESUMO

BACKGROUND: Muscle weakness and fatigue are common symptoms in multiple sclerosis (MS). Green tea catechins such as (-)epigallocatechin-3-gallate (EGCG) are known to improve energy metabolism at rest and during exercise. OBJECTIVE: We tested the hypothesis that EGCG improves energy metabolism and substrate utilization in patients with MS. DESIGN: Eighteen patients (8 men) with relapsing-remitting MS (expanded disability status scale score <4.5, all receiving glatiramer acetate) participated in this randomized, double-blind, placebo-controlled, crossover trial at a clinical research center. All patients received EGCG (600 mg/d) and placebo over 12 wk (4-wk washout in between). After each intervention, fasting and postprandial energy expenditure (EE), as well as fat oxidation (FAOx) and carbohydrate oxidation (CHOx) rates, were measured either at rest or during 40 min of exercise (0.5 W/kg). At rest, blood samples and microdialysates from adipose tissue and skeletal muscle were also taken. RESULTS: At rest, postprandial EE and CHOx, as well as adipose tissue perfusion and glucose supply, were significantly lower in men but higher in women receiving EGCG compared with placebo. During exercise, postprandial EE was lower after EGCG than after placebo, indicating an increased working efficiency (men > women). After placebo, exercise EE was mainly fueled by FAOx in both men and women. After EGCG, there was a shift to a higher and more stable CHOx during exercise in men but not in women. CONCLUSIONS: Our data indicate that EGCG given to patients with MS over 12 wk improves muscle metabolism during moderate exercise to a greater extent in men than in women, possibly because of sex-specific effects on autonomic and endocrine control.


Assuntos
Catequina/análogos & derivados , Suplementos Nutricionais , Metabolismo Energético , Esclerose Múltipla Recidivante-Remitente/dietoterapia , Músculo Esquelético/metabolismo , Fármacos Neuroprotetores/uso terapêutico , Gordura Subcutânea Abdominal/metabolismo , Adulto , Metabolismo dos Carboidratos/efeitos dos fármacos , Catequina/efeitos adversos , Catequina/uso terapêutico , Terapia Combinada/efeitos adversos , Estudos Cross-Over , Suplementos Nutricionais/efeitos adversos , Método Duplo-Cego , Metabolismo Energético/efeitos dos fármacos , Feminino , Acetato de Glatiramer , Humanos , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Metabolismo dos Lipídeos/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Atividade Motora , Esclerose Múltipla Recidivante-Remitente/tratamento farmacológico , Esclerose Múltipla Recidivante-Remitente/metabolismo , Esclerose Múltipla Recidivante-Remitente/fisiopatologia , Músculo Esquelético/efeitos dos fármacos , Fármacos Neuroprotetores/efeitos adversos , Peptídeos/efeitos adversos , Peptídeos/uso terapêutico , Período Pós-Prandial , Índice de Gravidade de Doença , Caracteres Sexuais , Gordura Subcutânea Abdominal/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...